

GenCore version 4.5
Copyright (c) 1993 - 2000 Comugen Ltd.

OM protein - protein search, using sw model

Run on: March 1, 2001, 16:10:11 ; Search time 64.32 Seconds
(without alignments)
14.354 Million cell updates/sec

Title: US-09-331-631A-31
Perfect score: 75
Sequence: 1 CXXCXXCXXXXXXCXXCXXC 27

Scoring table: BIOSUM62DX
Gapop 10.0 , Gapext 0.5

Searched: 268485 seqs, 34193795 residues
Total number of hits satisfying chosen parameters: 268485

Minimum DB seq length: 0
Maximum DB seq length: 200000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database :
1: A.Geneseq_36.*
2: /SIDSI/gcgdata/geneseq/geneseqp/AA1980.DAT.*
3: /SIDSI/gcgdata/geneseq/geneseqp/AA1981.DAT.*
4: /SIDSI/gcgdata/geneseq/geneseqp/AA1982.DAT.*
5: /SIDSI/gcgdata/geneseq/geneseqp/AA1983.DAT.*
6: /SIDSI/gcgdata/geneseq/geneseqp/AA1984.DAT.*
7: /SIDSI/gcgdata/geneseq/geneseqp/AA1985.DAT.*
8: /SIDSI/gcgdata/geneseq/geneseqp/AA1986.DAT.*
9: /SIDSI/gcgdata/geneseq/geneseqp/AA1987.DAT.*
10: /SIDSI/gcgdata/geneseq/geneseqp/AA1988.DAT.*
11: /SIDSI/gcgdata/geneseq/geneseqp/AA1989.DAT.*
12: /SIDSI/gcgdata/geneseq/geneseqp/AA1990.DAT.*
13: /SIDSI/gcgdata/geneseq/geneseqp/AA1991.DAT.*
14: /SIDSI/gcgdata/geneseq/geneseqp/AA1992.DAT.*
15: /SIDSI/gcgdata/geneseq/geneseqp/AA1993.DAT.*
16: /SIDSI/gcgdata/geneseq/geneseqp/AA1994.DAT.*
17: /SIDSI/gcgdata/geneseq/geneseqp/AA1995.DAT.*
18: /SIDSI/gcgdata/geneseq/geneseqp/AA1996.DAT.*
19: /SIDSI/gcgdata/geneseq/geneseqp/AA1997.DAT.*
20: /SIDSI/gcgdata/geneseq/geneseqp/AA1998.DAT.*
21: /SIDSI/gcgdata/geneseq/geneseqp/AA1999.DAT.*
22: /SIDSI/gcgdata/geneseq/geneseqp/AA2000.DAT.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	75	100.0	169	20	Y60558 Human normal blood
2	75	100.0	233	21	Y74791 Neisseria meningit
3	66	88.0	31	21	Y70731 Mnt antagonist pro
4	66	88.0	36	4	P30262 Sequence of peptid
5	66	88.0	36	4	P30263 Sequence of peptid
6	66	88.0	44	17	R96208 Nucleotide used in
7	66	88.0	60	14	R40209 Sequence of human
8	66	88.0	60	21	Y82332 Human metallothion
9	66	88.0	61	19	W61601 Human metallothion
10	66	88.0	61	21	Y82331 Human metallothion
11	66	88.0	61	21	Y57822 Rabbit liver metal
12	66	88.0	62	21	Y57810 Human metallothion

13	66	88.0	63	21	Y57811 Chicken metallothi
14	66	88.0	68	12	R14774 Brain-derived grow
15	66	88.0	68	13	R25720 Nerve nutrient act
16	66	88.0	68	15	R53383 Polypeptide having
17	66	88.0	103	20	Y37949 Chlamydia trachoma
18	66	88.0	109	17	R84086 T-Lymphocyte stimu
19	66	88.0	124	21	Y82334 Metallothionein ve
20	66	88.0	132	21	Y73470 Human secreted pro
21	66	88.0	219	18	W31759 A novel human h4-1
22	66	88.0	219	20	W92523 Human h4-1BBSV rec
23	66	88.0	219	20	W92524 Human h4-1BBSV rec
24	66	88.0	250	21	Y82335 Metallothionein ve
25	66	88.0	254	19	W64209 Oleosin-metallothi
26	66	88.0	255	16	R74087 Human receptor ind
27	66	88.0	255	16	R70977 H4-1BB receptor pr
28	66	88.0	255	16	R64197 Human 4-1BB polype
29	66	88.0	255	17	W04174 Human receptor H4-
30	66	88.0	255	18	W26558 Human 4-1BB recept
31	66	88.0	255	20	Y33214 Human CD137 protel
32	66	88.0	255	20	Y28688 Human receptor pro
33	66	88.0	392	20	Y35515 Chlamydia pneumonia
34	66	88.0	680	14	R34445 Sequence encoded b
35	66	88.0	680	19	W49015 Human KAL protein.
36	66	88.0	1040	20	W73584 RAG-1 protein. Mu
37	66	88.0	1214	21	Y79152 Mouse protein kina
38	65	86.7	57	21	Y57813 Crab metallothione
39	64.5	86.0	246	19	W53007 Mus musculus I-mfa
40	64.5	86.0	430	20	Y31745 Mycobacterium tube
41	64	85.3	66	21	Y64780 Human 5' EST relat
42	64	85.3	625	19	W62830 Macadamia integrif
43	64	85.3	666	19	W62828 Macadamia integrif
44	64	85.3	666	19	W62829 Macadamia integrif
45	63	84.0	690	19	W77414 Human sodium depen

ALIGNMENTS

RESULT 1	
Y60558	ID Y60558 standard; Protein; 169 AA.
XX	
AC	Y60558;
XX	
DT	31-JAN-2000 (first entry)
XX	
DE	Human normal bladder tissue EST encoded protein 230.
XX	
KW	Human: bladder; treatment; EST; expressed sequence tag; cytostatic;
KW	cancer; gene therapy.
XX	
OS	Homo sapiens.
XX	
PN	DE19818620-A1.
XX	
PD	28-OCT-1999.
XX	
PF	21-APR-1998; 98DE-1018620.
XX	
PR	21-APR-1998; 98DE-1018620.
XX	
PA	(META-) METAGEN GES GENOMFORSCHUNG MBH.
XX	
PI	Rosenthal A, Specht T, Hinzmann B, Schmitt A, Pilarsky C, Dahl E;
XX	
DR	WPI; 1999-602416/52.
XX	
DR	N-PSDB; 242235.
XX	
PT	New polypeptides and their nucleic acids, useful for treatment of
XX	bladder tumour and identification of therapeutic agents -
XX	
PS	Claim 23; Page 338; 366pp; German.
XX	

XX

FT		
F1	Misc-Reference	24
	/label = unknown	

FT Misc-difference :

```

FT /label= Unknown
FT Misc-difference 27
FT /label= Unknown
FT /note= "Xaa may be 7 amino acids in length; some
FT amino acids may be absent"
FT Misc-difference 29
FT /label= Unknown
FT /note= "Xaa may be 27 amino acids in length; some
FT amino acids may be absent"
FT /label= Unknown
FT /note= "Xaa may be 13 amino acids in length; some
FT amino acids may be absent"
XX WO200021555-A1.
XX
XX 20-APR-2000.
XX
XX 13-OCT-1999; 99WO-US23640.
XX
XX 15-OCT-1998; 98US-0104355.
XX
XX (HARD ) HARVARD COLLEGE.
XX
XX McMahon AP, Parr BA, Vaino S;
XX WPI; 2000-317845/27.
XX
XX Claim 12; Page 44; 57pp; English.
XX
XX The patent discloses a method of female primate contraception comprising
XX administering an antagonist of a Wnt polypeptide, inhibiting oocyte
XX development. Wnt polypeptides are useful for promotive maturation of an
XX immature oocyte. Wnt polypeptides are also useful for increasing the
XX number of mature oocytes and to enhance oocyte viability. The present
XX peptide is a consensus sequence of Wnt antagonist which inhibits the
XX physiological activity of a Wnt polypeptide. Antagonistic polypeptides
XX may contain a cysteine-rich domain.
XX
XX Sequence 31 AA:
XX
SQ
Query Match 88.0%; Score 66; DB 21; Length 31;
Best Local Similarity 65.4%; Pred. No. 38;
Matches 17; Conservative 9; Mismatches 0; Indels 0; Gaps 0.
QY 2 XXXXXCXXXXXXCXXCXXC 27
:::|||||:|||||:|
Db 5 cccccccccccccccccxcxc 30
RESULT 4
P30262
ID P30262 standard; peptide; 36 AA.
XX
XX P30262:
XX
XX 25-APR-1992 (first entry)
XX
XX Sequence of peptide used to vaccinate against E. coli enterotoxin(s).
XX
XX Vaccine; enterotoxin; diarrhoea; immunogen.
XX
XX Escherichia coli.
XX
XX Key location/Qualifiers
XX Misc-difference 1.18
XX /label= Peptide P
XX
XX EP93652-A.

```

XX	09-NOV-1983.
PD	
XX	
FE	26-APR-1983; 83EP-0072336.
XX	
PR	26-APR-1982; 82FR-0007179.
XX	
PA	(INSP) INST PASTEUR. (CNRS) CENT NAT RECH SCI.
PI	Tartar A, Duflot E, Boquet P;
DR	WPL; 1983-816301/46.
XX	
PT	Peptide(s) used to vaccinate against E. coli enterotoxin(s) - contg. e.g. asparagine threonine phenylalanine tyrosine cysteine cysteine glutamic acid leucine cysteine cysteine asparagine sequences
XX	
PS	Claim 1; Page 40; 50pp; French.
XX	
CC	The inventors claim peptides of formula (P) _n (see FT: see also P30263) having 4n-18n amino acids and pref. being laevorotatory CC (where n IS 1 or 2). In P30262 and P30263, N=2. When n IS 2, the peptide comprises two peptide sequences P, which may be the same or different, each having 4-18 amino acids chosen from the peptide P SO CC IN P30262 or P30263. The two P sequences may be joined (a) by a disulphide bond or (b) by a bond formed between a carboxyl gp. of one sequence of an amino gp. of the other.
XX	
Sequence	36 AA;

```

Query Match      88.0%; Score 66; DB 4; Length 36;
Best Local Similarity 18.5%; Pred. No. 43;
Matches 5; Conservative 21; Mismatches 1; Indels 0; Gaps 0;

QY      1 CXCXCXCXXXXXXXXXXCXCXCXCXC 27
        |::|::|::|::|::|::|::|::|
Db      6 celcncpacagcynltfycelcncpac 32

RESULT 5
P30263
ID      P30263 standard; peptide; 36 AA.
XX
XX      P30263;
XX
DT      25-APR-1992 (first entry)
DE      Sequence of peptide used to vaccinate against E. coli enterotoxin(s).
XX
XX      Vaccine; enterotoxin; diarrhoea; immunogen.
XX
XX      Escherichia coli.
XX
XX      Key Location/Qualifiers
FH      Misc-difference 1..18
FT      /label= Peptide P
XX
PN      EP93652-A.
XX
XX      09-NOV-1983.
XX
PF      26-APR-1983; 83EP-0072336.
XX
PR      26-APR-1982; 82FR-0007179.
XX
XX      (INSP ) INST PASTEUR.
PA      (CNRS ) CENT NAT RECH SCI.
XX
XX      Tartar A, Duflot E, Boquet P;
XX

```

XX	WP1; 1983-816301/46.
PR	Peptide(s) used to vaccinate against E. coli enterotoxin(s) -
PT	contg. e.g. asparagine threonine phenylalanine tyrosine cysteine
PP	cysteine glutamic acid leucine cysteine asparagine
PT	sequences
XX	
PS	Claim 1; Page 40; 50pp; French.
XX	
CC	The inventors claim peptides of formula (P)n (see PT; see also
CC	P30263) having 4n-18n amino acids and pref. being laevorotatory
CC	(where n is 1 or 2). In P30262 and P30263, N=2. When n is 2, the
CC	peptide comprises two peptide sequences P ₁ which may be the same or
CC	different, each having 4-18 amino acids chosen from the peptide P SQ
CC	In P30262 or P30263. The two P sequences may be joined (a) by a
CC	disulphide bond or (b) by a bond formed between a carboxyl gp. of
CC	one sequence of an amino gp. of the other.
XX	
SQ	Sequence 36 AA:
XX	
Query Match	88.0%; Score 66; DB 4; Length 36;
Best Local Similarity	18.5%; Pred. No. 43;
Matches	Conservative 21; Mismatches 1; Indels 0; Gaps
OY	1 CXCXCCXXXXXXXXXXXXCXXXCX 27 :: :: :: :: :: :: :: :: ::
DB	6 celcycpacagcnntfycelcycpac 32
RESULT	6
R98208	
ID	R98208 standard; Protein; 44 AA.
XX	
AC	R98208;
XX	
DT	30-DEC-1996 (first entry)
XX	
DE	Nucleotide used in production of MSH/MOMULV chimeric sequence.
XX	
KW	Moloney murine leukaemia virus; gp70; 4070A retrovirus; retrovirus;
KM	10A1 murine leukaemia virus; NZB-9-1 murine leukaemia virus;
KW	polytropic MK27 provirus; targeted drug delivery; gene therapy;
KK	single chain antibody; envelope protein; ss.
XX	
OS	Synthetic.
XX	
PN	WO9630504-A1.
XX	
PD	03-OCT-1996.
XX	
PE	22-MAR-1996; 96MO-USO3908.
XX	
PR	24-MAR-1995; 95US-0409648.
XX	
PA	(GENE-) GENETIC THERAPY INC.
PA	(UYSC-) UNIV SOUTHERN CALIFORNIA.
XX	
PI	Anderson W, Chiang YL, Januszski M, Mackrell AJ;
PI	Zhao Y;
DR	WP1; 1996-455352/45.
XX	
PT	Cell-targeted retroviral vector particles - having envelope protein
PT	modified with targeting polypeptide
XX	
PS	Example 2; Page 36; 73pp; English.
XX	
CC	Cell targeted retroviral vector particles can be used in gene
CC	expression of a heterologous gene to a target cell for
CC	tagged retroviral vector particles comprise an envelope protein
CC	which is modified to contain a targeting polypeptide (a single chain

```

CC antibody), or in the case of moloney murine leukemia virus
CC (MoMuLV), alpha melanotropin-stimulating hormone (MSH). Two
CC oligonucleotides (R98207, R98208) were used to substitute sequences in
CC MoMuLV for MSH sequences. This oligonucleotide was used to replace
CC residues G80-P88 of MoMuLV envelope protein (see W04248).
XX
SQ Sequence 44 AA;

Query Match 88.0%; Score 66; DB 17; Length 44;
Best Local Similarity 19.2%; Pred. No. 52;
Matches 5; Conservative 21; Mismatches 0; Indels 0; Gaps 0;

QY 2 XXXXXXXXXXXXXXXXXXXCXXCXXC 27
:::|::|::|::|::|::|::|::|::|
DB 13 tgcagccggtataactccctcac 38

RESULT 7
R40209 standard; protein; 60 AA.
XX
AC R40209;
XX
DT 04-FEB-1994 (first entry)
XX
DE Sequence of human metallothionein MT-2, class I.
XX
KW Metallothionein; MT-2; class I.
XX
OS Homo sapiens.
XX
PN DE4212134-A.
XX
PD 19-AUG-1993.
XX
PE 10-APR-1992; 92DE-4212134.
XX
PR 17-FEB-1992; 92GB-0003299.
XX
PA (INDE-) INDENA SPA.
XX
PI Bombardelli E, Ponzone C, Puglisi PP;
XX
DR WP1; 1993-265710/34.
XX
PT Topical compsn. for protecting tissue e.g. skin - against toxic
PT heavy metals, contg. metal-complexing protein with high cysteine
PT content
XX
PS Disclosure: Page 3; 7pp; German.
XX
CC Class I metallothioneins are characterised by a high Cys content and
CC the absence of aromatic AAs; a molecular weight of 6000-7000;
CC characteristic thio-metal complexes and clusters;
CC and a high metal content.
XX
SQ Sequence 60 AA;

Query Match 88.0%; Score 66; DB 14; Length 60;
Best Local Similarity 19.2%; Pred. No. 70;
Matches 5; Conservative 21; Mismatches 0; Indels 0; Gaps 0;

QY 1 CXXCXXCXXXXXXXXXXXXCXXCXXC 26
|::|::|::|::|::|::|::|::|::
DB 25 ctscckscscscpcpycackcagcgick 50

RESULT 8
Y82332 standard; protein; 60 AA.
XX

```


[illegible]

```

XX      27-NOV-1991.
PD      XX
XX      PE      07-MAY-1991;          91EP-0401221.
XX      PR      13-DEC-1990;         90JP-0410165.
PR      PR      09-NOV-1990;         90JP-0119620.
PR      PR      13-DEC-1990;         90JP-0410164.
XX      PA      ('TSUJ') TSUJI S.
XX      PI      Tsuji S., Miyatake T., Uchida Y., Ihara Y.;
XX      DR      WPI, 1991-3148330/48.
DR      N-PsDB; Q14778.
XX      PT      New growth-inhibitor factor extracted from human brain - has
PT      and treating Alzheimer's disease.
PS      Claim 6; page 7; 15pp; English.
CC      The sequence was deduced from a clone isolated from a cDNA library
CC      prep'd. from RNA extracted from human brain, and also sequenced
CC      using a protein sequecer from protein purified from human cerebral
CC      cortex tissue. The protein has a mol. wt. of 5,000 (SDS Page) and
CC      has growth inhibiting activity in humans. It is not found in the
CC      brains of patients with Alzheimer's disease and may be useful for
CC      the treatment or prophylaxis of this disease.
SX      Sequence      68 AA:
SQ
OY      Query Match              88.0%; Score 66; DB 12; Length 68;
        Best Local Similarity   19.2%; Pred.No. 79;
        Matches     5; Conservative    21; Mismatches      0; Indels     0; Gaps       0.
        Db           1 CXCXKXXXXXXXXXXXXCXXXCX 26
                |::|::::::::::||::|::|
        27 ctscckscscspceckeckadcvck 52

RESULT 15
R25720 ID R25720 standard; Protein; 68 AA.
AC      R25720;
AD      DT      18-JAN-1993 (first entry)
DE      XX      Nerve nutrient activity inhibiting peptide.
KW      XX      Cerebral protein; pH range; Alzheimers disease.
OS      Synthetic.
PN      JP04169600-A.
PD      PD      17-JUN-1992.
PE      PE      13-DEC-1990;         90JP-0410164.
PR      PR      19-OCT-1990;         90JP-0279371.
PA      (UCHI/) UCHIDA Y.
WPI; 1992-253557/31.
N-PsDB; Q26711.
Human cerebral protein inhibits nerve nutrient activity - for
treating and diagnosing Alzheimer's disease
Claim 4; Page 2; 20pp; Japanese.
```

